Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma
- PMID: 22570617
- PMCID: PMC3343074
- DOI: 10.1371/journal.pgen.1002654
Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma
Abstract
Optic nerve degeneration caused by glaucoma is a leading cause of blindness worldwide. Patients affected by the normal-pressure form of glaucoma are more likely to harbor risk alleles for glaucoma-related optic nerve disease. We have performed a meta-analysis of two independent genome-wide association studies for primary open angle glaucoma (POAG) followed by a normal-pressure glaucoma (NPG, defined by intraocular pressure (IOP) less than 22 mmHg) subgroup analysis. The single-nucleotide polymorphisms that showed the most significant associations were tested for association with a second form of glaucoma, exfoliation-syndrome glaucoma. The overall meta-analysis of the GLAUGEN and NEIGHBOR dataset results (3,146 cases and 3,487 controls) identified significant associations between two loci and POAG: the CDKN2BAS region on 9p21 (rs2157719 [G], OR = 0.69 [95%CI 0.63-0.75], p = 1.86×10⁻¹⁸), and the SIX1/SIX6 region on chromosome 14q23 (rs10483727 [A], OR = 1.32 [95%CI 1.21-1.43], p = 3.87×10⁻¹¹). In sub-group analysis two loci were significantly associated with NPG: 9p21 containing the CDKN2BAS gene (rs2157719 [G], OR = 0.58 [95% CI 0.50-0.67], p = 1.17×10⁻¹²) and a probable regulatory region on 8q22 (rs284489 [G], OR = 0.62 [95% CI 0.53-0.72], p = 8.88×10⁻¹⁰). Both NPG loci were also nominally associated with a second type of glaucoma, exfoliation syndrome glaucoma (rs2157719 [G], OR = 0.59 [95% CI 0.41-0.87], p = 0.004 and rs284489 [G], OR = 0.76 [95% CI 0.54-1.06], p = 0.021), suggesting that these loci might contribute more generally to optic nerve degeneration in glaucoma. Because both loci influence transforming growth factor beta (TGF-beta) signaling, we performed a genomic pathway analysis that showed an association between the TGF-beta pathway and NPG (permuted p = 0.009). These results suggest that neuro-protective therapies targeting TGF-beta signaling could be effective for multiple forms of glaucoma.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures



References
-
- Caprioli J, Varma R. Intraocular pressure: modulation as treatment for glaucoma. Am J Ophthalmol. 2011;152:340–344. - PubMed
-
- Grover DS, Budenz DL. Ocular perfusion pressure and glaucoma. Int Ophthalmol Clin. 2011;5:19–25. - PubMed
-
- Wang X, Harmon J, Zabrieskie N, Chen Y, Grob S, Williams B, et al. Using the Utah Population Database to assess familial risk of primary open angle glaucoma. Vision Res. 2010;50:2391–2395. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 EY011671/EY/NEI NIH HHS/United States
- EY012118/EY/NEI NIH HHS/United States
- P01 CA055075/CA/NCI NIH HHS/United States
- T32 EY021453/EY/NEI NIH HHS/United States
- R01 EY013178/EY/NEI NIH HHS/United States
- R01 EY015473/EY/NEI NIH HHS/United States
- R01 EY011405/EY/NEI NIH HHS/United States
- EY009149/EY/NEI NIH HHS/United States
- R01 EY022306/EY/NEI NIH HHS/United States
- EY144428/EY/NEI NIH HHS/United States
- U01 HG004728/HG/NHGRI NIH HHS/United States
- U01 HG004446/HG/NHGRI NIH HHS/United States
- U01-HG004424/HG/NHGRI NIH HHS/United States
- P30 EY005722/EY/NEI NIH HHS/United States
- HL73042/HL/NHLBI NIH HHS/United States
- T32EY021453/EY/NEI NIH HHS/United States
- R01 HG004037/HG/NHGRI NIH HHS/United States
- R01 EY011008/EY/NEI NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- EY18660/EY/NEI NIH HHS/United States
- EY015473/EY/NEI NIH HHS/United States
- EY015872/EY/NEI NIH HHS/United States
- EY010886/EY/NEI NIH HHS/United States
- CA87969/CA/NCI NIH HHS/United States
- P01 HL073042/HL/NHLBI NIH HHS/United States
- EY009847/EY/NEI NIH HHS/United States
- CA55075/CA/NCI NIH HHS/United States
- U01 HG004424/HG/NHGRI NIH HHS/United States
- R01 HL073389/HL/NHLBI NIH HHS/United States
- EY011671/EY/NEI NIH HHS/United States
- CA49449/CA/NCI NIH HHS/United States
- EY13315/EY/NEI NIH HHS/United States
- HG005259-01/HG/NHGRI NIH HHS/United States
- EY015682/EY/NEI NIH HHS/United States
- R01 EY012118/EY/NEI NIH HHS/United States
- R01 EY015543/EY/NEI NIH HHS/United States
- R56 EY011671/EY/NEI NIH HHS/United States
- R01 EY020928/EY/NEI NIH HHS/United States
- R01 EY021818/EY/NEI NIH HHS/United States
- R01 EY008208/EY/NEI NIH HHS/United States
- HG004608/HG/NHGRI NIH HHS/United States
- HG004728/HG/NHGRI NIH HHS/United States
- HHSN268200782096C/HG/NHGRI NIH HHS/United States
- EY013178/EY/NEI NIH HHS/United States
- EY006827/EY/NEI NIH HHS/United States
- R01 EY019126/EY/NEI NIH HHS/United States
- R03 EY015682/EY/NEI NIH HHS/United States
- R01 EY022305/EY/NEI NIH HHS/United States
- P20 RR015574/RR/NCRR NIH HHS/United States
- U54 HG004570/HG/NHGRI NIH HHS/United States
- EY011008/EY/NEI NIH HHS/United States
- RC1 HG005334/HG/NHGRI NIH HHS/United States
- R01 EY009580/EY/NEI NIH HHS/United States
- U10 EY012118/EY/NEI NIH HHS/United States
- U54HG004570/HG/NHGRI NIH HHS/United States
- R01 CA049449/CA/NCI NIH HHS/United States
- R01 EY015872/EY/NEI NIH HHS/United States
- R01 EY009847/EY/NEI NIH HHS/United States
- R01 EY010886/EY/NEI NIH HHS/United States
- U01 CA049449/CA/NCI NIH HHS/United States
- HL073389/HL/NHLBI NIH HHS/United States
- EY09580/EY/NEI NIH HHS/United States
- 3R01EY019126-02S1/EY/NEI NIH HHS/United States
- EY015543/EY/NEI NIH HHS/United States
- EY008208/EY/NEI NIH HHS/United States
- U01 HG004608/HG/NHGRI NIH HHS/United States
- R01 EY013315/EY/NEI NIH HHS/United States
- RR015574/RR/NCRR NIH HHS/United States
- R01 EY018660/EY/NEI NIH HHS/United States
- RC1HG005334/HG/NHGRI NIH HHS/United States
- EY144448/EY/NEI NIH HHS/United States
- 3R01EY015872-05S1/EY/NEI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous